Monday, 27 June 2022

Vietnam signs MoU with India for COVID-19 vaccine

24 September 2021 | News

Nanogen has developed and produced protein subunit vaccine

Image Credit: PIB

Image Credit: PIB

Translational Health Science and Technology Institute (THSTI), Department of Biotechnology (DBT), Government of India has entered into a research collaboration with Nanogen Pharmaceutical Biotechnology JSC, a Vietnamese pharmaceutical company, that is developing a new vaccine for COVID-19.

Pham Sanh Chau, the Ambassador of Vietnam to India, led a team that visited THSTI to sign MoU between THSTI and the Nanogen Pharmaceutical Biotechnology JSC. 

After having accomplished the pre-clinical trial with high safety and efficacy, Nano Covax is the first COVID-19 vaccine to be approved by Vietnam’s Ministry of Health to conduct clinical trial in Vietnam. Phase 1 of the clinical trial started on December 2020.

Nanogen has developed and produced protein subunit vaccine by using recombinant S-protein subunit binding to silica nanoparticles.

The current manufactory system of Nanogen is capable of manufacturing 20-30 million doses, up to 100 million doses each year to satisfy the domestic demand and export orientation. 



Sign up for the editor pick and get articles like this delivered right to your inbox.

Editors Pick
+Country Code-Phone Number(xxx-xxxxxxx)


× Your session has been expired. Please click here to Sign-in or Sign-up
   New User? Create Account